CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) plus rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).
Document type:
Meeting Abstract
Author(s):
Pachynski, Russell Kent; Retz, Margitta; Goh, Jeffrey C.; Burotto, Mauricio; Gravis, Gwenaelle; Castellano, Daniel; Flechon, Aude; Zschaebitz, Stefanie; Shaffer, David R.; Limon, Juan Carlos Vazquez; Grimm, Marc-Oliver; McCune, Steven L.; Amin, Neha P.; Li, Jia; Wang, Xuya; Unsal-Kacmaz, Keziban; Saad, Fred; Petrylak, Daniel P.; Fizazi, Karim
Login
BibTeX